Table 3.

Patient risk factors for brain metastasis

Patients	Months to CNS metastasis	Sex	Primary site	Primary type	Primary Clark level	Primary Breslow score (mm)	Primary ulceration status	Number of involved LNs	Metastasis grade	LDH
1	12.00	Male	H&N	Cut	Unknown	Unknown	Unknown	> 3	M1c	nl
2	NA	Male	Unknown	Unknown	Unknown	Unknown	Unknown	> 3	M1a	nl
3	NA	Male	Nail	Acro	IV	6.20	Ulc	> 3	M1c	High
4	4.33	Female	Chest  wall	Cut	IV	0.80	nUlc	> 3	M1c	High
5	2.86	Male	H&N	Nodular	IV	4.90	nUlc	> 3	M1c	High
6	5.33	Male	Trunk	Cut	IV	4.30	Ulc	0	M1c	High
7	1.66	Female	Trunk	Cut	Unknown	4.75	nUlc	> 3	M1c	nl
8	5.33	Male	Sinus	Mucosal	Unknown	Unknown	Unknown	> 3	M1c	nl
9	NA	Female	Unknown	Unknown	Unknown	Unknown	Unknown	> 3	M1c	nl

Arco, acrolentiginous; CNS, central nervous system; Cut, cutaneous; H&N, head and neck; LDH, lactate dehydrogenase; LN, lymph node; NA, not applicable (patient did not develop CNS yet); nl, normal; nUlc, nonulcerated; Ulc, ulcerated.